Adams May Cough Up Humibid As Product Confusion Congests Sales
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics is considering whether to stop offering its Humibid 1,200 mg guaifenesin product, which it markets voluntarily behind the counter, as it launches an over-the-counter version of the same product under the name Maximum Strength Mucinex
You may also be interested in...
Max Strength Mucinex Sales Could Reach $70M In Debut Season – Adams
Adams Respiratory Therapeutics projects sales of its forthcoming Maximum Strength Mucinex products will eventually make up 60 percent of total Mucinex sales, the firm said April 4
Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
In the midst of strong growth from flagship brand Mucinex, Adams is delaying the launch of new Humibid products to train pharmacists in behind-the-counter sale of the OTC drug
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line